Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is dedicated to developing targeted drugs in the field of cancer treatment. The company has established strategic partnerships with leading antibody companies Medarex, Biosite, and Amgen, utilizing its unique OGAP® (Oxford Genome Anatomy Project) platform to build a series of novel antibody therapeutics. OGAP® is one of the largest proprietary human protein databases in the world, containing and integrating proteomic and genomic data along with associated clinical information. OBT also intends to develop companion diagnostics for selected antibody programs. The company aims to improve disease management and treatment outcomes by integrating diagnostic capabilities into product development and commercialization activities.